Literature DB >> 8741199

Minor changes on cranial MRI during treatment in children with acute lymphoblastic leukaemia.

E Pääkkö1, L Vainionpää, J Pyhtinen, M Lanning.   

Abstract

Cranial MRI was used to study treatment-related changes in children undergoing therapy for acute lymphoblastic leukaemia (ALL) or lymphoma. Nineteen children (18 with ALL, 1 with lymphoma) underwent MRI at the beginning of treatment and at intervals during it, to a total of 105 imaging studies and a minimum of 3 per case. Nine patients had finished all therapy, all received consolidation treatment. No patient had central nervous system (CNS) leukaemia at diagnosis or developed a CNS relapse. Mild treatment-related white matter changes were observed in only 2 patients after consolidation therapy with three 5 g/m2 pulses of intravenous methotrexate. Transient enlargement of the ventricles and cortical sulci was observed in 13 patients, always temporally related to steroid treatment. These preliminary data suggest that treatment-related white matter changes are rare and no routine MRI follow-up is needed during treatment in asymptomatic children after a baseline assessment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8741199     DOI: 10.1007/bf00596544

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  28 in total

1.  Transient neurologic disturbances in a child treated with moderate-dose methotrexate.

Authors:  C Borgna-Pignatti; L Battisti; P Marradi; R Balter; R Caudana
Journal:  Br J Haematol       Date:  1992-07       Impact factor: 6.998

2.  Transient cerebral dysfunction secondary to high-dose methotrexate.

Authors:  R W Walker; J C Allen; G Rosen; B Caparros
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

3.  Central nervous system toxicity with high-dose cytosine arabinoside.

Authors:  R H Herzig; H M Lazarus; G P Herzig; P F Coccia; S N Wolff
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

4.  High-dose cytarabine neurotoxicity: MR findings during the acute phase.

Authors:  D J Vaughn; J G Jarvik; D Hackney; S Peters; E A Stadtmauer
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

5.  Decrease in cerebral metabolic rate of glucose after high-dose methotrexate in childhood acute lymphocytic leukemia.

Authors:  K Komatsu; G Takada; K Uemura; F Shishido; I Kanno
Journal:  Pediatr Neurol       Date:  1990 Sep-Oct       Impact factor: 3.372

6.  MR findings in methotrexate-induced CNS abnormalities.

Authors:  F Ebner; G Ranner; I Slavc; C Urban; R Kleinert; H Radner; R Einspieler; E Justich
Journal:  AJNR Am J Neuroradiol       Date:  1989 Sep-Oct       Impact factor: 3.825

7.  Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.

Authors:  N Wollner; J H Burchenal; P H Lieberman; P Exelby; G D'Angio; M L Murphy
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

8.  Acute cerebellar dysfunction with high-dose ARA-C therapy.

Authors:  M C Salinsky; R L Levine; J P Aubuchon; H S Schutta
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

Review 9.  Radiation injury of the brain.

Authors:  P E Valk; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  1991-01       Impact factor: 3.825

10.  Steroids and apparent cerebral atrophy on computed tomography scans.

Authors:  J Bentson; M Reza; J Winter; G Wilson
Journal:  J Comput Assist Tomogr       Date:  1978-01       Impact factor: 1.826

View more
  10 in total

1.  Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study.

Authors:  M E Carey; M W Haut; S L Reminger; J J Hutter; R Theilmann; K L Kaemingk
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

2.  Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features.

Authors:  France Ziereisen; Bernard Dan; Nadira Azzi; Alina Ferster; Nash Damry; Catherine Christophe
Journal:  Pediatr Radiol       Date:  2005-12-21

3.  How PET/MR Can Add Value For Children With Cancer.

Authors:  Heike Daldrup-Link
Journal:  Curr Radiol Rep       Date:  2017-02-21

4.  Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome.

Authors:  Nancy Rollins; Naomi Winick; Robert Bash; Timothy Booth
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

Review 5.  Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.

Authors:  Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui
Journal:  AJNR Am J Neuroradiol       Date:  2005-05       Impact factor: 3.825

Review 6.  Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae.

Authors:  Fred H Laningham; Larry E Kun; Wilburn E Reddick; Robert J Ogg; E Brannon Morris; Ching-Hon Pui
Journal:  Neuroradiology       Date:  2007-10-09       Impact factor: 2.804

Review 7.  Diffusion-weighted MRI in neuro-oncology.

Authors:  Joachim M Baehring; Robert K Fulbright
Journal:  CNS Oncol       Date:  2012-11

Review 8.  Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia.

Authors:  Wilburn E Reddick; Fred H Laningham; John O Glass; Ching-Hon Pui
Journal:  Neuroradiology       Date:  2007-07-26       Impact factor: 2.804

9.  MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging.

Authors:  M S M Chan; D J Roebuck; M-P Yuen; C-K Li; Y-L Chan
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

10.  Cranial MRI in Childhood Acute Leukemia during Treatment and Follow-Up Including the Impact of Intrathecal MTX-A Single-Center Study and Review of the Literature.

Authors:  Marvin Mergen; Sascha Scheid; Hannah Schubmehl; Martin Backens; Wolfgang Reith; Norbert Graf
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.